Salicylic Acid
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Salicylic Acid
- Salicylic Acid: From Topical Skin and Inflammatory Conditions to Papillary Conjunctivitis
Salicylic Acid: From Topical Skin and Inflammatory Conditions to Papillary Conjunctivitis
One-Sentence Summary
Salicylic acid is a long-established agent used mainly in topical skin products, with original indications including acne, fungal skin infections (tinea), seborrheic dermatitis and warts. The TxGNN model predicts it may be effective for papillary conjunctivitis, but there are currently 0 clinical trials and 0 publications supporting this prediction. It rests on model output alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the Singapore licence records. The knowledge graph lists tinea pedis, acne, seborrheic dermatitis, rheumatoid arthritis, allergic rhinitis and others |
| Predicted New Indication | Papillary conjunctivitis |
| TxGNN Prediction Score | 99.88% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available. Based on known information, salicylic acid is thought to act through inhibition of COX enzymes, reducing prostaglandin synthesis, and has anti-inflammatory and keratolytic (skin-softening) effects. Public bioactivity data to confirm this at a specific molecular target could not be found, so this mechanism remains unconfirmed.
Papillary conjunctivitis is an inflammatory, often allergic, condition of the eye surface. Salicylic acid's anti-inflammatory activity, and its use in related conditions such as allergic rhinitis, offer a theoretical link. However, this link is speculative. The drug is marketed in Singapore only as skin-applied products (lotions, ointments, solutions, creams, a shampoo), and application near the eye raises concerns about irritation and corneal toxicity.
Other top-ranked predictions (for example rosacea conjunctivitis and spondyloarthropathy) have similarly weak or indirect support. Several others are rare genetic skeletal disorders with no plausible mechanistic link, which suggests the high scores partly reflect knowledge-graph artefacts rather than true therapeutic potential.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
Twenty valid single-ingredient licences are registered. The licence records do not include approved indication text. The five main authorisations are listed below.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN09177P | ICM White Spot Lotion 5% | Lotion | Not stated |
| SIN04701P | Centa Skin Lotion 2% w/v | Lotion | Not stated |
| SIN02882P | Salicylic Acid 2% Cream | Cream | Not stated |
| SIN13728P | Collomack Salicylic Acid Solution 10% | Solution | Not stated |
| SIN04047P | Duofilm Collodion | Tincture | Not stated |
Safety Considerations
- Drug Interactions: One pharmacology-based entry was found, relating to the acid-sensing ion channel ASIC3 (a molecular target rather than a co-administered drug). No graded interaction level is available.
Please refer to the package insert for other safety information, including warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by the model score, with no clinical trials or literature. The mechanism is unconfirmed, and the available Singapore products are all for skin use, with safety concerns for ocular application. Other predicted indications are even less plausible.
To proceed, the following is needed:
- Package insert warnings and contraindications from the Singapore regulator (HSA)
- Confirmed mechanism of action data
- Preclinical or clinical evidence of benefit in conjunctival inflammation
- Ocular safety and tolerability assessment, and a suitable ophthalmic formulation and route
- If a better-supported direction is wanted, evaluating the spondyloarthropathy prediction, which has the most plausible indirect link through anti-inflammatory activity
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.